Incyte to Report First Quarter Financial Results
The schedule for the press release and conference call/webcast is as follows:
- Q1 2026 Press Release: April 28, 2026 at 7:00 a.m. ET
- Q1 2026 Conference Call: April 28, 2026 at 8:00 a.m. ET
- Domestic Dial-In Number: 877-407-3042
- International Dial-In Number: 201-389-0864
- Conference ID Number: 13759527
If you are unable to participate, a replay of the conference call will be available for thirty days. The replay dial-in number for the
The live webcast with slides can be accessed at Investor.Incyte.com and will be available for replay for ninety days.
About Incyte®
Incyte is redefining what’s possible in biopharmaceutical innovation. Through deep scientific expertise and a relentless focus on patients, we have built an established portfolio of first-in-class medicines and an extensive portfolio of next-generation medicines across our key franchises: Hematology, Oncology and Inflammation and Autoimmunity.
To learn more, visit Incyte.com and Investor.Incyte.com. Follow us on social media: LinkedIn, X and Instagram.
View source version on businesswire.com: https://www.businesswire.com/news/home/20260409506560/en/
Incyte Contacts
Media
media@incyte.com
Investors
ir@incyte.com
Source: Incyte